Cardiff Oncology, Inc. (NASDAQ:CRDF) Q3 2023 Earnings Call Transcript

Mark Erlander: No, it’s not. It’s really we’re watching as it’s open label. So it’s going to depend on the magnitude of the effect that we do see. So but there is no trigger in the protocol.

Joe Catanzaro: Okay, got it. That’s very helpful. Thanks for taking my question.

Mark Erlander: Sure, Joe.

Operator: Our next question comes from the line of Andy Hsieh with William Blair.

Andy Hsieh: Great, thanks for taking my questions and congratulations on all the progress. Two questions, if you don’t mind. One has to do with, Mark, I believe when you were conducting the Phase 1b/2 study before, there was a strategy employed to minimize the adverse event from switching between bolus 5-FU and infusional 5-FU. I’m just curious if that strategy is also being employed in 004 and 005. And then I’d love to hear, obviously with this expanded pipeline development plan, I’d love to hear your thoughts on the IP strategy in terms of market exclusivity. Thank you.

Mark Erlander: Okay. With the first question, Andy, regarding the bolus, we’re continuing to have that be an optional for the treatment arms. And — but in the control arm, the FDA has asked that they consider it to be standard care to have the 5-FU bolus. But we will continue to do what we’ve done in the Phase 1b/2 trial. Your second question, maybe, Andy, maybe you could repeat that again just so I make sure I answer that correctly.

Operator: Thank you. At this time, I would now like to turn the conference back over to Mark Erlander for closing remarks.

Mark Erlander: Well, thank you all for your time, and this concludes our conference call and thank you once again for joining us this afternoon.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.